HPRA Drug Safety Newsletter Edition 107

Download: hpra-drug-safety-newsletter-edition-107.pdf 243 KB

 The latest edition of the HPRA Drug Safety Newsletter includes information and updates on the following medicines:

Paxlovid - Interactions between ritonavir component and other medicines leading to clinically significant interactions

Transmucosal fentanyl - labelling update to mitigate the risks of off-lable use, accidental ingestion or unintentional exposure

Product information updates recommended by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) for:
  - Ibuprofen containing medicines: Acute Generalised Exanthematous Pustulosis (AGEP)
  - Aimovig (erenumab): constipation and hypersensitivity reactions
  - Emgality (galcanezumab): hypersensitivity reactions

« Back